---
title: "Jazz Q2 FY26 GAAP EPS rises 16% to $2.78; revenue increases 16% to $1.21 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294732976.md"
description: "Jazz Pharmaceuticals reported Q2 FY26 GAAP EPS of $2.78, up 16% YoY, with revenue reaching $1.21 billion, also a 16% increase. Key drivers included growth in Xywav, Epidiolex/Epidyolex, Zepzelca, and Modeyso. The company raised its full-year 2026 revenue guidance to $4.6-$4.75 billion from the previous range of $4.25-$4.5 billion."
datetime: "2026-08-03T20:14:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294732976.md)
  - [en](https://longbridge.com/en/news/294732976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294732976.md)
generator: "portal-rs"
---

# Jazz Q2 FY26 GAAP EPS rises 16% to $2.78; revenue increases 16% to $1.21 billion

-   Jazz Pharmaceuticals posted 2Q26 revenue of $1.21 billion, up 16% year over year, as GAAP net income swung to $192.8 million. \* GAAP diluted EPS was $2.78; non-GAAP adjusted EPS was $5.71. \* Xywav revenue rose 13% to $471.2 million; Epidiolex/Epidyolex climbed 16% to $292.1 million. \* Zepzelca revenue increased 42% to $105.8 million; Modeyso delivered $48.2 million in revenue. \* 2026 revenue guidance was raised to $4.6 billion-$4.75 billion from $4.25 billion-$4.5 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608031605PR\_NEWS\_USPR\_\_\_\_\_SF17345) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [Jazz Pharmaceuticals prices upsized USD 1.1 billion exchangeable senior notes offering due 2032](https://longbridge.com/en/news/297122954.md)
- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [These Analysts Increase Their Forecasts On Jazz Pharmaceuticals](https://longbridge.com/en/news/297066303.md)
- [JAZZ: FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new standard of care](https://longbridge.com/en/news/296933637.md)
- [Jazz Pharmaceuticals highlights Ziihera launch, targets $3-$5 billion zanidatamab peak sales opportunity](https://longbridge.com/en/news/297016685.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**